Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. (Q39003793)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

title

Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Rebecca C Arend

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Angelina I Londoño-Joshi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Rajeev S Samant

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Yonghe Li

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Michael Conner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Bertha Hidalgo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Ronald D Alvarez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Charles N Landen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

J Michael Straughn

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

language of work or name

English

0 references

publication date

13 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

volume

134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

page(s)

112-120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

14 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Anticancer effects of niclosamide in human glioblastoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Growth inhibition of ovarian tumor-initiating cells by niclosamide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Cancer stem cells: impact, heterogeneity, and uncertainty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Roles and regulation of Wnt signaling and beta-catenin in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Wnt signaling in stem and cancer stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Targeting Wnt signaling: can we safely eradicate cancer stem cells?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Wnt proteins induce dishevelled phosphorylation via an LRP5/6- independent mechanism, irrespective of their ability to stabilize beta-catenin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Multiplicity of the interactions of Wnt proteins and their receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

Comprehensive molecular portraits of human breast tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.04.005

10.1016/J.YGYNO.2014.04.005

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24736023%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference